• レポートコード:PMR201205 • 出版社/出版日:Persistence Market Research / 2020年9月25日 • レポート形態:英文、PDF、293ページ • 納品方法:Eメール • 産業分類:生命科学 |
Single User | ¥725,200 (USD4,900) | ▷ お問い合わせ |
Site Licence | ¥1,124,800 (USD7,600) | ▷ お問い合わせ |
Enterprisewide | ¥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは生物製剤受託製造の世界市場について調査・分析し、エグゼクティブサマリー、市場概要、主要市場動向、市場背景、新型コロナウイルス感染症の危機影響分析、市場動向、需要分析・予測、価格分析、製品別(成長因子、インターフェロン、モノクローナル抗体、組換えホルモン、 ワクチン)、プラットホーム別(哺乳類、微生物)、治療領域別(自己免疫疾患、腫瘍学、代謝性疾患、眼科、心血管疾患)、用途別(臨床、商業)、地域別分析、市場構造分析、競争分析、仮定、調査手法などの項目を掲載しています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・市場背景 ・新型コロナウイルス感染症の危機影響分析 ・市場動向 ・需要分析・予測 ・価格分析 ・生物製剤受託製造の世界市場規模:製品別(成長因子、インターフェロン、モノクローナル抗体、組換えホルモン、 ワクチン) ・生物製剤受託製造の世界市場規模:プラットホーム別(哺乳類、微生物) ・生物製剤受託製造の世界市場規模:治療領域別(自己免疫疾患、腫瘍学、代謝性疾患、眼科、心血管疾患) ・生物製剤受託製造の世界市場規模:用途別(臨床、商業) ・生物製剤受託製造の世界市場規模:地域別 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Biologics Contract Manufacturing Demand – Scope of the Report
Persistence Market Research (PMR) recently published a market study on the global market for biologics contract manufacturing demand. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities, restraints, and detailed information about the biologics contract manufacturing demand structure. The market study presents exclusive information about how biologics contract manufacturing demand will grow during the forecast period of 2020-2030.
Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of biologics contract manufacturing demand during the forecast period.
The study is relevant for stakeholders interested in biologics contract manufacturing demand, including biologics contract manufacturing service organizations, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in biologics contract manufacturing demand, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in PMR’s study.
The study also includes statistics as well as facts related to the macro- as well as micro-economic factors that are impacting developments in the market. It also offers actionable insights based on the future trends regarding biologics contract manufacturing demand. Furthermore, small businesses and new entrants related to biologics contract manufacturing demand too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.
Key Questions Answered in PMR’s Biologics Contract Manufacturing Demand Study
How will CDMO services demand unfold over the coming years?
Which regions will continue to remain the most profitable regional markets for players dealing with biologics contract manufacturing demand?
Which factors will induce a change in biologics contract manufacturing demand during the assessment period?
How will changing trends impact biologics contract manufacturing demand?
How can market players capture the low-hanging opportunities related to biologics contract manufacturing demand in developed regions?
Which companies are leading in biologics contract manufacturing demand?
What are the winning strategies of stakeholders involved in biologics contract manufacturing demand services to upscale their position in this landscape?
Biologics Contract Manufacturing Demand: Research Methodology
In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of biologics contract manufacturing demand, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the biologics contract manufacturing demand market study include statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies dealing in biologics contract manufacturing demand, and makes PMR’s projections on the growth prospects of the market space more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Competitive Snapshot, Capacity (kL)
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting The Market
3.2. Product Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Healthcare Expenditure Outlook
4.1.3. Growth of Healthcare Sector in Emerging Nations
4.2. Forecast Factors – Relevance & Impact
4.2.1. Global Increase in Healthcare Expenditure
4.2.2. Strong biologics pipeline fuel demand for the CMOs
4.2.3. Corporate Venture Capital Investments are Helping Advance Biotechnology R&D
4.2.4. Changing regulatory dynamics are hampering the growth of Biopharmaceutical contract manufacturing market
4.2.5. CMO Cost Impact
4.2.6. Regulatory Scenario
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis
5. COVID19 Crisis Impact Analysis
5.1. COVID19 Crisis Impact Analysis
5.1.1. Current COVID19 Statistics and Probable Future Impact
5.1.2. Current GDP Projection and Probable Impact
5.1.3. Current Economic Projection as compared to 2008 Economic analysis
5.1.4. COVID19 and Impact Analysis
5.2. Biopharmaceutical Contract Manufacturing Market Capacity Analysis
5.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)
5.2.1.1. By Product
5.2.1.2. By Therapeutic Area
5.2.1.3. By Platform
5.2.1.4. By Application
5.2.1.5. By Region (including especially EU/U.K./U.S.)
5.2.2. Manufacturing Capacity Expansion for COVID-19 Related Products
5.3. Biopharmaceutical Contract Manufacturing Market Demand Analysis
5.3.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)
5.3.1.1. By Product
5.3.1.2. By Therapeutic Area
5.3.1.3. By Platform
5.3.1.4. By Application
5.3.1.5. By Region (including especially EU/U.K./U.S.)
5.3.2. Covid-19 Impact Pricing Analysis
5.3.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)
5.3.3. Capacity Utilization Analysis
5.3.3.1. Initiation of COVID-19 related Products Contract Manufacturing
5.3.3.2. Timeframe of Capacity and Slot Utilization for COVID-related Products
5.3.4. 2020 Market Scenario
5.3.5. Quarter by Quarter Forecast
5.3.6. Projected Recovery Quarter
5.4. Impact on Trends Analysis
5.4.1. Single-Use
5.4.2. Modular
5.4.3. Consolidation
5.5. Recovery Scenario – Short term, Midterm and Long Term Impact
6. Market Context
6.1. Product Adoption / Usage Analysis
6.2. Promotional Strategies by Key Players
6.3. Key Industry Deals
6.4. Regulatory Scenario
7. Global Biopharmaceutical Contract Manufacturing Market Capacity (in kL/Units) Analysis 2015-2019 and Forecast, 2020–2030
7.1. Historical Market Capacity (in kL/Units) Analysis, 2015-2019
7.2. Current and Future Market Capacity (kL/Units) Projections, 2020-2030
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute Capacity (in kL/Units) Opportunity Analysis
8. Global Biopharmaceutical Contract Manufacturing Market – Pricing Analysis
8.1. Regional Pricing Analysis, By Services
8.2. Global Average Pricing Analysis Benchmark
9. Global Biopharmaceutical Contract Manufacturing Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020–2030
9.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
9.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, by Product
10.1. Introduction / Key Findings
10.2. Historical Market Capacity (in kL) Analysis By Product, 2015 – 2019
10.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Product, 2020 – 2030
10.3.1. Growth Factors
10.3.2. Interferons
10.3.3. Monoclonal Antibodies
10.3.4. Recombinant Hormones
10.3.5. Vaccines
10.3.6. Insulin
10.3.7. Others
10.4. Market Attractiveness Analysis By Product
11. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Platform
11.1. Introduction / Key Findings
11.2. Historical Market Capacity (in kL) Analysis By Platform, 2015 – 2019
11.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Platform, 2020 – 2030
11.3.1. Mammalian
11.3.2. Microbial
11.4. Market Attractiveness Analysis By Platform
12. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Therapeutic Area
12.1. Introduction / Key Findings
12.2. Historical Market Capacity (in kL) Analysis By Therapeutic Area, 2015 – 2019
12.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Therapeutic Area, 2020 – 2030
12.3.1. Autoimmune Diseases
12.3.2. Oncology
12.3.3. Metabolic Diseases
12.3.4. Ophthalmology
12.3.5. Cardiovascular Diseases
12.3.6. Infectious Diseases
12.3.7. Neurology
12.3.8. Respiratory Disorders
12.3.9. Others
12.4. Market Attractiveness Analysis By Therapeutic Area
13. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Application
13.1. Introduction / Key Findings
13.2. Historical Market Capacity (in kL) Analysis By Application, 2015 – 2019
13.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Application, 2020 – 2030
13.3.1. Clinical
13.3.2. Commercial
13.4. Market Attractiveness Analysis By Application
14. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, by Region
14.1. Introduction
14.2. Historical Market Capacity (in kL) Analysis By Region, 2015 – 2019
14.3. Current Market Capacity (in kL) Analysis and Forecast By Region, 2020 – 2030
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region
15. North America Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030
15.1. Introduction
15.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019
15.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 – 2030
15.3.1. By Country
15.3.1.1. U.S.
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Platform
15.3.4. By Therapeutic Area
15.3.5. By Application
15.4. Market Attractiveness Analysis
16. Latin America Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030
16.1. Introduction
16.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019
16.3. Market Size Capacity (in kL) Forecast By Taxonomy, 2020 – 2030
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Platform
16.3.4. By Therapeutic Area
16.3.5. By Application
16.4. Market Attractiveness Analysis
17. Europe Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030
17.1. Introduction
17.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019
17.3. Market Capacity (in kL) Forecast By Market, 2020 – 2030
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. U.K.
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Rest of Europe
17.3.2. By Product
17.3.3. By Platform
17.3.4. By Therapeutic Area
17.3.5. By Application
17.4. Market Attractiveness Analysis
18. South Asia Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030
18.1. Introduction
18.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019
18.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 – 2030
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Thailand
18.3.1.3. Indonesia
18.3.1.4. Malaysia
18.3.1.5. Rest of South Asia
18.3.2. By Product
18.3.3. By Platform
18.3.4. By Therapeutic Area
18.3.5. By Application
18.4. Market Attractiveness Analysis
19. East Asia Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030
19.1. Introduction
19.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019
19.3. Market Size Capacity (in kL) Forecast By Taxonomy, 2020 – 2030
19.3.1. By Country
19.3.1.1. China
19.3.1.2. Japan
19.3.1.3. South Korea
19.3.2. By Product
19.3.3. By Platform
19.3.4. By Therapeutic Area
19.3.5. By Application
19.4. Market Attractiveness Analysis
20. Oceania Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030
20.1. Introduction
20.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019
20.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 – 2030
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Platform
20.3.4. By Therapeutic Area
20.3.5. By Application
20.4. Market Attractiveness Analysis
21. Middle East and Africa Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030
21.1. Introduction
21.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 – 2019
21.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 – 2030
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. South Africa
21.3.1.3. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Platform
21.3.4. By Therapeutic Area
21.3.5. By Application
21.4. Market Attractiveness Analysis
22. Key and Emerging Countries Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030
22.1. U.S. Biopharmaceutical Contract Manufacturing Demand Analysis
22.1.1. By Product
22.1.2. By Platform
22.1.3. By Therapeutic Area
22.1.4. By Application
22.2. Canada Biopharmaceutical Contract Manufacturing Demand Analysis
22.2.1. By Product
22.2.2. By Platform
22.2.3. By Therapeutic Area
22.2.4. By Application
22.3. U.K. Biopharmaceutical Contract Manufacturing Demand Analysis
22.3.1. By Product
22.3.2. By Platform
22.3.3. By Therapeutic Area
22.3.4. By Application
22.4. Germany Biopharmaceutical Contract Manufacturing Demand Analysis
22.4.1. By Product
22.4.2. By Platform
22.4.3. By Therapeutic Area
22.4.4. By Application
22.5. France Biopharmaceutical Contract Manufacturing Demand Analysis
22.5.1. By Product
22.5.2. By Platform
22.5.3. By Therapeutic Area
22.5.4. By Application
22.6. Spain Biopharmaceutical Contract Manufacturing Demand Analysis
22.6.1. By Product
22.6.2. By Platform
22.6.3. By Therapeutic Area
22.6.4. By Application
22.7. Italy Biopharmaceutical Contract Manufacturing Demand Analysis
22.7.1. By Product
22.7.2. By Platform
22.7.3. By Therapeutic Area
22.7.4. By Application
23. Market Structure Analysis
23.1. Market Analysis by Tier of Companies
23.2. Market Share Analysis of Top Players
23.3. Market Concentration
23.4. Market Presence Analysis
23.4.1. By Regional Footprint of Players
23.4.2. Product Footprint by Players
23.4.3. Channel Footprint by Players
24. Competition Analysis
24.1. Competition Dashboard
24.2. CDMO Capability & Capacity Analysis 2020
24.3. Competition Deep Dive
24.3.1. BioXcellence (Boehringer Ingelheim GmbH)
24.3.1.1. Overview
24.3.1.2. Product Portfolio
24.3.1.3. Key Financial
24.3.1.4. Sales Footprint
24.3.1.5. Analyst commentary
24.3.2. Lonza Group AG
24.3.2.1. Overview
24.3.2.2. Product Portfolio
24.3.2.3. Key Financial
24.3.2.4. Sales Footprint
24.3.2.5. Analyst commentary
24.3.3. Samsung Biologics Co. Ltd.
24.3.3.1. Overview
24.3.3.2. Product Portfolio
24.3.3.3. Key Financial
24.3.3.4. Sales Footprint
24.3.3.5. Analyst commentary
24.3.4. Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
24.3.4.1. Overview
24.3.4.2. Product Portfolio
24.3.4.3. Key Financial
24.3.4.4. Sales Footprint
24.3.4.5. Analyst commentary
24.3.5. AbbVie Contract Manufacturing (AbbVie Inc.)
24.3.5.1. Overview
24.3.5.2. Product Portfolio
24.3.5.3. Key Financial
24.3.5.4. Sales Footprint
24.3.5.5. Analyst commentary
24.3.6. WuXi Biologics (Cayman) Inc.
24.3.6.1. Overview
24.3.6.2. Product Portfolio
24.3.6.3. Key Financial
24.3.6.4. Sales Footprint
24.3.6.5. Analyst commentary
24.3.7. Patheon N.V. (Thermo Fisher Scientific Inc.)
24.3.7.1. Overview
24.3.7.2. Product Portfolio
24.3.7.3. Key Financial
24.3.7.4. Sales Footprint
24.3.7.5. Analyst commentary
24.3.8. Emergent BioSolutions Inc.
24.3.8.1. Overview
24.3.8.2. Product Portfolio
24.3.8.3. Key Financial
24.3.8.4. Sales Footprint
24.3.8.5. Analyst commentary
24.3.9. AGC Biologics
24.3.9.1. Overview
24.3.9.2. Product Portfolio
24.3.9.3. Key Financial
24.3.9.4. Sales Footprint
24.3.9.5. Analyst commentary
24.3.10. Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
24.3.10.1. Overview
24.3.10.2. Product Portfolio
24.3.10.3. Key Financial
24.3.10.4. Sales Footprint
24.3.10.5. Analyst commentary
24.3.11. Avid Bioservices, Inc.
24.3.11.1. Overview
24.3.11.2. Product Portfolio
24.3.11.3. Key Financial
24.3.11.4. Sales Footprint
24.3.11.5. Analyst commentary
24.3.12. KBI Biopharma (JSR Life Sciences (JLS))
24.3.12.1. Overview
24.3.12.2. Product Portfolio
24.3.12.3. Key Financial
24.3.12.4. Sales Footprint
24.3.12.5. Analyst commentary
24.3.13. Catalent Inc.
24.3.13.1. Overview
24.3.13.2. Product Portfolio
24.3.13.3. Key Financial
24.3.13.4. Sales Footprint
24.3.13.5. Analyst commentary
24.3.14. Abzena Plc.
24.3.14.1. Overview
24.3.14.2. Product Portfolio
24.3.14.3. Key Financial
24.3.14.4. Sales Footprint
24.3.14.5. Analyst commentary
25. Assumptions and Acronyms Used
26. Research Methodology
Table 01: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By ProductTable 02: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 03: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Product
Table 04: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 05: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 06: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 07: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 08: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 09: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Application
Table 10: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Region
Table 11: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Region
Table 12: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 13: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 14: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 15: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 16: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 17: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 18: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 19: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 20: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 21: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 22: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 23: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 24: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 25: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 26: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 27: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 28: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 29: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 30: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 31: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 32: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 33: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 34: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 35: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 36: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 37: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 38: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 39: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 40: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 41: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 42: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 43: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 44: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 45: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 46: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 47: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 48: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 49: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 50: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 51: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 52: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 53: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 54: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 55: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 56: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 57: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 58: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 59: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 60: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 61: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 62: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 63: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 64: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 65: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 66: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 67: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 68: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 69: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 70: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 71: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 72: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 73: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application